Global Imbruvica Market Overview:
Imbruvica is an inhibitor of Bruton’s tyrosine kinase. Imbruvica is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy; for the treatment of chronic lymphocytic leukemia /small lymphocytic lymphoma; for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion; and for chronic graft versus host disease (cGVHD) after the failure of one or more lines of system therapy.
- Increasing Prevalence of Cancer Diseases Across the World
- Rising Number of Patients with Lymphomas and Leukemia
- Side Effect Imbruvica such as Upset Stomach, Diarrhea, Nausea, Vomiting, Decreased Appetite, etc.
- Rising Healthcare Sector Across the World
- Growing Cancer Treatment with Specified Treatment Drugs
- Stringent Regulatory Process
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new drug launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies
Some of the key players profiled in the report are AbbVie Inc.(Pharmacyclics) (United States), Johnson & Johnson (Janssen Biotech) (United States), SP Laboratories (Serbia), Beacon Pharmaceuticals (Bangladesh), Incepta Pharmaceuticals (Bangladesh) and Bluepharma (Portugal). Considering Market by Drug Form, the sub-segment i.e. Tablet will boost the Imbruvica market. Considering Market by Tablets, the sub-segment i.e. 140mg will boost the Imbruvica market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Imbruvica market.
In April 2020, The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy., and In Dec 2019, Hyderabad-based Natco Pharma NSE -0.34 % has launched a cut-price version of ibrutinib, an anti-cancer drug, under its own brand name Ibrunat. The patent for the drug is held by Pharmacyclics for three to four more years in India.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Imbruvica market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Imbruvica market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Imbruvica Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.